Lantidra’s First-Cycle Complete Response Letter Centered On Inspection And Product Quality Issues
Executive Summary
Although the CRL delayed the cell therapy’s approval by almost two years, additional CMC-related testing requested by the FDA ultimately came to be seen as a good thing by sponsor CellTrans because it provided assurance of product consistency.
You may also be interested in...
Lantidra Chronology: 19 Years From IND Submission To Approval For The Cellular Therapy
Pink Sheet’s Drug Review Profile looks at the timeline behind the development and FDA review of CellTrans’ treatment for type 1 diabetes.
CellTrans’ Donislecel Gets US FDA Panel Nod For Small Group Of Type 1 Diabetics
Benefits of independence from exogenous insulin outweighed the risks from long-term immunosuppression necessary with the allogeneic pancreatic islet cellular therapy, majority of panelists said, but they urged the FDA to limit the indication to a very small subpopulation of patients.
BrainStorm’s NurOwn Gets Many, Many Thumbs Down From US FDA Panel
In overwhelmingly concluding that efficacy has not been demonstrated for the mesenchymal stromal cell therapy, panelists went beyond just the failed Phase III trial and cited BrainStorm’s ‘statistical magic’ and failure to adequately describe the mechanism of action, as well as safety and product quality concerns.